CD8A and plasma cell myeloma: A higher proportion of CD8+ CD45RO- CD27+ memory T cells and a higher CD4+/CD8+ ratio in leukapheresis products created to generate T cells against multiple myeloma are linked to improved expansion in vivo and a positive clinical response in patients.66